Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Eloxatin

- PMLiVE

Blue Latitude Health expands into the US

New York City office will be led by James Atherton

Eli Lilly HQ

Lilly and Boehringer combine breast cancer drugs in trial

Firms anticipate together the two drugs will offer a “more complete pathway interference”

- PMLiVE

Gilead’s Zydelig passes EMA safety review

Risk of ‘serious infections’ outweighed by cancer drug’s benefits

Case Study: Oncology diagnostic biomarker landscaping study

The challenge:Our client needed to understand moleculardiagnostic testing growth opportunities for a new biomarker in oncology. They wanted to understand the current market landscape, identify potential leverage points that would maximise use of the biomarker...

Research Partnership

Bristol-Myers Squibb (BMS) building

Bristol-Myers Squibb acquires Cormorant for $520m

Deal with Swedish firm will boost BMS' oncology pipeline

- PMLiVE

Pfizer set to snap up Bind’s assets for $20m

Biotech approves 'stalking horse' bid from the pharma giant

Bristol-Myers Squibb (BMS) building

NICE ‘no’ for Opdivo in kidney cancer

BMS oncology drug knocked-back in draft guidance

- PMLiVE

Amgen’s Kyprolis wins new indication in Europe

Regulators have handed the treatment a less restrictive licence in multiple myeloma 

- PMLiVE

Digital influencer marketing

How good stories can drive value for brands, products and companies

- PMLiVE

NICE finally set to back wider use of Ferring’s Firmagon

And acknowledges drug's benefits for prostate cancer that spreads to the spine

- PMLiVE

Sweet emotion

Are we harnessing the full emotional power of brand creativity?

Celgene building

Celgene takes aim at cancer innovation with new US research consortium

Academic tie-up aims to develop new therapeutics and diagnostics

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links